Mouiz Elbashir's Contact Details

Mouiz Elbashir's Company Details

Bio-Map Europe

Princeton, New Jersey, United States • 2 Employees
Research

If you are an innovative, SME Biotech company, in the clinic, with a potential approval in the next 3-4 years, but concerned about the evidence you will need to achieve successful pricing & reimbursement in the highly complex European markets, Bio-MAP Europe was designed specifically for you.Bio-MAP Europe contains all the elements you will need from Value Strategy, Pricing, Clinical & HEOR Evidence to Value Communication, in one easy-to-use, comprehensive service package. Spanning the development of Market Access strategy right through Value Story & economic model development, to pricing & reimbursement dossier preparation we can even take care of individual country pricing & reimbursement dossier submission and Payer negotiation in Europe if you do not yet have the infrastructure in place.Bio-MAP Europe is delivered by GalbraithWight, the leading global strategic Market Access Consultancy, with over 20 years' Thought Leadership & successful experience delivering Market Access solutions for major global brands such as Yervoy, Opdivo, Keytruda, Ibrance, Eliquis and many more.We work with a wide range of highly innovative Biotech companies including Kite Pharma, Halozyme and Illumina. Your project will be led by one of our team of highly experienced Consultants, each with an average of 20 years industry experience, which means they understand the pressures you are facing, and are focussed on delivering the right result for you and your new medicine. The benefits:1. your precious clinical trial investment works harder2. your innovation stands a much better chance of reaching those patients who need it most, through a clear, proven, systematic roadmap ensuring the right steps are taken at the right time, with the right deliverables, with the right quality3. your investors and shareholders may realize a higher level return on investment through a robust Market Access plan4. current and future investors' confidence in eventual commercial success is increased